IP Library Granted Patent US 10,220,079
Granted Patent B2
US 10,220,079 · App. 15/822,573 · Granted Mar 5, 2019

Suture line administration technique using botulinum toxins

Inventor: Andrew M. Blumenfeld (Del Mar, CA)
Assignee: Allergan, Inc.
A61K38/4893C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,079
App. No.
15/822,573
Granted
Mar 5, 2019
Kind
B2
Abstract

The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.

Claims (20)

1. A method for treating a patient suffering from a headache, comprising the step of administering a Clostridial toxin between the periosteum and the aponeurotic fascia of the scalp in the vicinity of at least one suture line of the patient's skull, wherein the administration alleviates at least one symptom of the headache, thereby treating the patient suffering from the headache.

2. The method according to claim 1 , wherein the Clostridial neurotoxin is a botulinum toxin.

3. The method according to claim 1 , wherein the headache is selected from the group consisting of a sinus headache, a tension headache, a migraine headache, a cluster headache and a cervogenic headache.

4. The method according to claim 1 , wherein the at least one suture line is selected from the group consisting of frontal suture, squamous suture, occipitomastoid suture, coronal suture, lambdoid suture and sagittal suture.

5. The method according to claim 2 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.

6. The method according to claim 5 , wherein the botulinum toxin is botulinum toxin type A.

7. The method according to claim 6 , wherein amount of botulinum toxin type A administered is from about 5 units to about 1000 units.

8. The method according to claim 1 , wherein the headache is an episodic migraine or a chronic migraine.

9. The method of claim 1 , further comprising the step of administering the Clostridial toxin in the vicinity of a second suture line.

10. The method of claim 1 , wherein the Clostridial neurotoxin is administered at about 1.5 cm, about 1.0 cm, or about 0.5 cm from the at least one suture line.

11. A method for alleviating a headache pain, comprising the step of determining the location of at least one suture line; and administering a therapeutically effective amount of botulinum toxin type A to a patient in need thereof, wherein the botulinum toxin type A is administered between the periosteum and the aponeurotic fascia of the scalp in the vicinity of the at least one suture line of the patient's skull, thereby alleviating the headache pain.

12. The method of claim 11 , wherein the at least one suture line is selected from the group consisting of frontal suture, squamous suture, coronal suture, lambdoid suture, occipitomastoid suture and sagittal suture.

13. The method of claim 11 , wherein the amount of administered botulinum toxin type A is from about 5 units to about 1000 units.

14. The method according to claim 12 , wherein two or more of the frontal, squamous, coronal, lamboidal and sagittal sutures are administered botulinum toxin type A.

15. The method of claim 11 , wherein the administration step includes the step of inserting a needle of a syringe containing the botulinum toxin type A at a needle penetration point, and positioning the needle along the at least one suture line so that the botulinum toxin type A is administered linearly along at least a portion of the at least one suture line.

16. The method of claim 11 , further comprising the step of administering the botulinum toxin type A in the vicinity of a second suture line.

17. The method of claim 15 , wherein one needle penetration point is utilized to administer the botulinum toxin type A in the vicinity of at least two suture lines.

18. The method of claim 11 , wherein the botulinum toxin type A is administered at about 1.5 cm, about 1.0 cm, or about 0.5 cm from the at least one suture line.

19. The method of claim 1 , wherein the administering is subdermal or subcutaneous.

20. The method of claim 11 , wherein the administrating is subdermal or subcutaneous.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2017
From: BLUMENFELD, ANDREW M.
To: ALLERGAN, INC.
Reel/Frame 044224/0046 →
Continuity (4)
Continuation 15012259 · Feb 1, 2016
Continuation 14086760 · Nov 21, 2013
Continuation 12062372 · Apr 3, 2008
Related Publication 20180078622A1 · Mar 22, 2018